rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in
Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate
BP patients. The study population will consist of patients above the age of 18 years with an
active episode of BP, confirmed by inclusion and exclusion criteria and who, in the opinion
of the Investigator, would benefit from treatment with rVA576. Recombinant rVA576 is a small
protein complement C5 and LTB4 inhibitor, which prevents the cleavage of C5 by C5 convertase
and thereby inhibits generation of C5b-9 the membrane attack complex (MAC), as well as
preventing the release of the anaphylatoxin C5a. rVA576 is effective in inhibiting terminal
complement activity irrespective of the activating pathway (classical, lectin or
alternative). This Phase IIa open-label single-arm study will evaluate the safety and
efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid patients